Phaseline

Targets › PCYT1A

PCYT1A (Choline-phosphate cytidylyltransferase A): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Ophthalmology; next expected readout Apr 2027.

Catalyzes the key rate-limiting step in the CDP-choline pathway for phosphatidylcholine biosynthesis. (UniProt, P49585)

Open in Phaseline: the race on PCYT1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Omikron Italia S.r.l.Citicoline eye drops 2%
Phosphatidylcholine precursor with neuroprotective properties
PCYT1APhase 3Glaucoma, Open-AngleApr 2027

Conditions

Glaucoma, Open-Angle (1)

Modalities

small molecule (1)

Companies

Omikron Italia S.r.l. (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.